Orbis Medicines Secures €90 Million Series A Funding to Revolutionize Oral Macrocycle Drug Discovery

Funding Round:
Orbis Medicines has closed a €90 million Series A funding round, bringing the total amount raised by the company to €116 million1 2.

Investors:
The funding was led by New Enterprise Associates (NEA) with participation from new investors including Eli Lilly and Company, Cormorant, the Export and Investment Fund of Denmark, and returning investors Novo Holdings and Forbion1 4.

Purpose:
The funds will support the development of Orbis’ pipeline of next-generation oral macrocycle drugs, known as “nCycles,” which aim to offer oral alternatives to blockbuster biologic drugs1 2.

Leadership:
Morten Graugaard has been named the Chief Executive Officer of Orbis Medicines, bringing over 20 years of experience in life sciences to the leadership team1.

Technology Platform:
Orbis Medicines uses its proprietary nGen platform to systematically explore macrocycle chemical space and deliver oral macrocycle drug candidates suitable for both intra- and extracellular targets3 5.

Market Potential:
The company aims to pioneer a new era for oral macrocycle drug discovery, addressing the historical challenges in developing macrocycles as oral drugs1 5.